In its largest deal since 1995, Albany Molecular Research Inc. exclusively licensed a portfolio of biogenic amine reuptake inhibitors to Bristol-Myers Squibb Co. for the development of drugs to treat depression and other central nervous system disorders. (BioWorld Today)
In its largest deal since 1995, Albany Molecular Research Inc. exclusively licensed a portfolio of biogenic amine reuptake inhibitors to Bristol-Myers Squibb Co. for the development of drugs to treat depression and other central nervous system disorders. (BioWorld Today)
Reporting a 19 percent increase in product sales over last year, Amgen Inc. topped consensus estimates for the three months ending Sept. 30, though its revenue fell short of expectations. (BioWorld Today)
